200 related articles for article (PubMed ID: 30246405)
1. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.
Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N
Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405
[TBL] [Abstract][Full Text] [Related]
2. Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo.
Sakai K; Kato D; Yoshinaka J; Takahashi Y; Ikeda N; Aoki S; Iguchi T; Ishikawa S; Yamagishi N; Shimamura S; Nakagawa T
Vet Comp Oncol; 2024 Jun; 22(2):230-238. PubMed ID: 38502572
[TBL] [Abstract][Full Text] [Related]
3. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival.
Gustafson TL; Kitchell BE; Biller B
Vet Comp Oncol; 2017 Mar; 15(1):174-183. PubMed ID: 25864514
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
J Vet Med Sci; 2022 May; 84(5):666-674. PubMed ID: 35387955
[TBL] [Abstract][Full Text] [Related]
6. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder.
Tsuboi M; Sakai K; Maeda S; Chambers JK; Yonezawa T; Matsuki N; Uchida K; Nakayama H
Vet Pathol; 2019 May; 56(3):369-376. PubMed ID: 30612533
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
8. Effects of calcitriol, seocalcitol, and medium-chain triglyceride on a canine transitional cell carcinoma cell line.
Kaewsakhorn T; Kisseberth WC; Capen CC; Hayes KA; Calverley MJ; Inpanbutr N
Anticancer Res; 2005; 25(4):2689-96. PubMed ID: 16080513
[TBL] [Abstract][Full Text] [Related]
9. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand.
Lin TY; Zhang H; Wang S; Xie L; Li B; Rodriguez CO; de Vere White R; Pan CX
Mol Cancer; 2011 Jan; 10(1):9. PubMed ID: 21272294
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.
Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW
J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
12. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma.
Vinall RL; Kent MS; deVere White RW
Am J Vet Res; 2012 Oct; 73(10):1626-33. PubMed ID: 23013190
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
14. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.
Knapp DW; Ramos-Vara JA; Moore GE; Dhawan D; Bonney PL; Young KE
ILAR J; 2014; 55(1):100-18. PubMed ID: 24936033
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
Maeda S; Sakai K; Kaji K; Iio A; Nakazawa M; Motegi T; Yonezawa T; Momoi Y
Sci Rep; 2022 Jan; 12(1):4. PubMed ID: 35027594
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
19. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Bai M; Song N; Che X; Wang X; Qu X; Liu Y
Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
[TBL] [Abstract][Full Text] [Related]
20. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
